Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2003. The report primarily addresses corporate governance updates, specifically changes to Board committee responsibilities and disclosures regarding directors' interests in company shares.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on administrative and governance matters rather than financial performance.
Material Changes
Effective February 7, 2003, the Board of GlaxoSmithKline implemented the following changes to committee leadership and membership:
- Nominations Committee: Sir Ian Prosser was appointed Chairman, replacing Sir Christopher Hogg, who remains a member.
- Remuneration Committee: Sir Peter Job was appointed as a new member.
- Corporate Social Responsibility Committee: Mr. Donald McHenry was appointed Chairman, replacing Sir Christopher Hogg, who remains a member.
Additionally, on February 7, 2003, the SmithKline Beecham Employee Benefit Trust transferred 4,784 Ordinary shares to participants of the 1991 Share Option Plan. Directors Dr. J.P. Garnier and John Coombe hold interests in these shares as beneficiaries of the Trust.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the updated composition of the Nominations, Remuneration, and Corporate Social Responsibility Committees as of February 7, 2003.
- Confirm the transfer of 4,784 Ordinary shares from the Employee Benefit Trust to the 1991 Share Option Plan.
- Note that this filing contains no financial performance data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.